Skip to content
Eternygen GmbH
  • ABOUT US
    • TEAM
    • BOARD
    • OBSERVERS
    • ADVISORS
  • SCIENCE
    • R&D
    • LITERATURE & PAPERS
  • NEWS
    • PRESS & NEWS
    • FOUNDERS IN THE NEWS
  • CONTACT
  • DE / EN

Category: press statement – en

08/02/2023

October 2022 – Meet Eternygen at BioEurope conference in Leipzig from 23-26 October 2022

press statement - en by eternygenFlorian0 comments
Meet Eternygen at BioEurope conference in Leipzig from 23-26 October 2022.
Read more>>
08/02/2023

September 2022 – Dr. Grit Zahn, Head of Research of Eternygen GmbH will present at the biotx.ai webinar on 29th September 2022

press statement - en by eternygenFlorian0 comments
Dr. Grit Zahn, Head of Research of Eternygen GmbH will present at the biotx.ai webinar on 29th September 2022. Link
Read more>>
08/02/202308/02/2023

September 2022 – Dr. Grit Zahn, Head of Research of Eternygen GmbH will be speaking at TESS Research Foundation’s International Research Conference in Vienna 7-8 September 2022

press statement - en by eternygenFlorian0 comments
Dr. Grit Zahn, Head of Research of Eternygen GmbH will be speaking at TESS Research Foundation's International Research Conference in [...]
Read more>>
26/10/202009/06/2021

October 2020 – Eternygen Announces the First Closing of its Series A2 Funding Round

press statement - en by eternygenFlorian0 comments

Eternygen Announces the First Closing of its Series A2 Funding Round

Read more>>
22/04/202008/02/2023

April 2020 – Eternygen is nominated for the “German Accelerator Life Sciences” programme

press statement - en by eternygenFlorian0 comments

News of Eternygen

Read more>>
22/04/202009/06/2021

April 2020 – Eternygen is presenting at „BioLaunchPad, the company showcase platform of BioTrinity” from 28 April – 1 May 2020.

press statement - en by eternygenFlorian0 comments

Eternygen is presenting at „BioLaunchPad, the company showcase platform of BioTrinity” from 28 April – 1 May 2020. Link

Read more>>
24/03/202009/06/2021

March 2020 – Dr. Grit Zahn, Head of Research of Eternygen GmbH presents at the 4th International SLC13A5 Deficiency Research Roundtable of the Tess research foundation in March 2020.

press statement - en by eternygenFlorian0 comments

Dr. Grit Zahn, Head of Research of Eternygen GmbH presents at the 4th International SLC13A5 Deficiency Research Roundtable of the […]

Read more>>
10/02/202009/06/2021

February 2020 – Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH

press statement - en by eternygenFlorian0 comments

Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH Press statement

Read more>>
09/01/202009/06/2021

Meet Eternygen at the Biotech Showcase conference 2020 in San Francisco, CA, USA

press statement - en by eternygenFlorian0 comments

Meet Eternygen at the Biotech Showcase conference 2020 in San Francisco, CA, USA Eternygen is attending the Biotech Showcase conference […]

Read more>>
07/01/202009/06/2021

Meet Eternygen at BioEurope conference in Hamburg from November 11th to 13th 2019

press statement - en by eternygenFlorian0 comments

Meet Eternygen at BioEurope conference in Hamburg from November 11th to 13th Eternygen will attend the BioEurope conference in Hamburg […]

Read more>>
01/10/201909/06/2021

Prof. Birkenfeld was appointed as Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the University Clinic Tübingen

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld was appointed as Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the […]

Read more>>
30/03/201809/06/2021

Prof. Birkenfeld was awarded with the Abstract Award

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld was awarded with the Abstract Award Prof. Birkenfeld was awarded with the Abstract Award by the American College […]

Read more>>
20/11/201709/06/2021

Eternygen at BioFIT 2017

press statement - en by eternygenFlorian0 comments

Eternygen at BioFIT 2017 Eternygen was invited to join panel discussion at BioFIT 2017 conference “How are collaborations key to […]

Read more>>
20/10/201709/06/2021

Prof. Birkenfeld is chairman of the working group diabetes and heart

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld is chairman of the working group diabetes and heart Prof. Birkenfeld is the new chairman of the working […]

Read more>>
18/09/201709/06/2021

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany)

press statement - en by eternygenFlorian0 comments

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany) Press release

Read more>>
09/01/201709/06/2021

Eternygen GmbH closes € 8.0 (US$ 8.3) million Series A financing

press statement - en by eternygenFlorian0 comments

Eternygen GmbH closes € 8.0 (US$ 8.3) million Series A financing Eternygen GmbH Closes € 8.0 (US$ 8.3) million Series […]

Read more>>
08/12/201609/06/2021

Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine

press statement - en by eternygenFlorian0 comments

Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine “Prof. Jordan takes on position as Head […]

Read more>>
08/12/201609/06/2021

TransCampus Network between TU Dresden and King’s College London receives €5million grant

press statement - en by eternygenFlorian0 comments

TransCampus Network between TU Dresden and King’s College London receives €5million grant The TransCampus network between King’s and Technische Universität […]

Read more>>
20/06/201609/06/2021

Eteryngen at 7th International IQPC Conference

press statement - en by eternygenFlorian0 comments

Eteryngen at 7th International IQPC Conference Eternygen GmbH today announced that its head of research will present at the 7th International […]

Read more>>
12/05/201613/01/2020

Prof. Birkenfeld to take over the succession of Prof. Markolf Hanefeld at centre of clinical studies in Dresden

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld to take over the succession of Prof. Markolf Hanefeld at centre of clinical studies in Dresden Interview by […]

Read more>>
08/02/201609/06/2021

Prof. Jordan receives renowned Peter Sleight Award

press statement - en by eternygenFlorian0 comments

Prof. Jordan receives renowned Peter Sleight Award Prof. Jordan receives renowned Peter Sleight Award of the european society of Hypertension […]

Read more>>
01/05/201509/06/2021

Prof. Birkenfeld to receive renowned Ferdinand Bertram price

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld to receive renowned Ferdinand Bertram price Press statement of GWT (in German) Article in Sächsische Zeitung (in German)

Read more>>
21/04/201509/06/2021

BioEquity Europe Conference

press statement - en by eternygenFlorian0 comments

BioEquity Europe Conference Eternygen GmbH will present a corporate overview of the company at the 16 th BioEquity Europe Conference, […]

Read more>>
01/01/201509/06/2021

Creation of a Transcampus between TU Dresden and King’s College London

press statement - en by eternygenFlorian0 comments

Creation of a Transcampus between TU Dresden and King’s College London PubMed Article Introduction of Transcampus Initiative by King’s College […]

Read more>>
10/09/201409/06/2021

Prof. Birkenfeld transfers to TU Dresden

press statement - en by eternygenFlorian0 comments

Prof. Birkenfeld transfers to TU Dresden Press statement GWT (in German) 

Read more>>
06/05/201409/06/2021

Evotec and Eternygen Cooperation

press statement - en by eternygenFlorian0 comments

Evotec and Eternygen Cooperation Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy. download press statement

Read more>>
05/09/201309/06/2021

Dr. Grit Zahn new head of research

press statement - en by eternygenFlorian0 comments

Dr. Grit Zahn new head of research Eternygen appoints Dr. Grit Zahn as Head of Research. download press statement

Read more>>
28/07/201309/06/2021

Eternygen GmbH receives funding

press statement - en by eternygenFlorian0 comments

Eternygen GmbH receives funding Eternygen GmbH receives funding from IBB Beteiligungsgesellschaft. download press statement

Read more>>

Recent Posts

  • October 2022 – Meet Eternygen at BioEurope conference in Leipzig from 23-26 October 2022
  • September 2022 – Dr. Grit Zahn, Head of Research of Eternygen GmbH will present at the biotx.ai webinar on 29th September 2022
  • September 2022 – Dr. Grit Zahn, Head of Research of Eternygen GmbH will be speaking at TESS Research Foundation’s International Research Conference in Vienna 7-8 September 2022
  • August 2022 – Eternygen published new paper on SLC13A5 inhibitors titled: “A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity”
  • April 2022 – Prof. Andreas Birkenfeld and Dr. Grit Zahn are Guest editing a Special Issue on “I’m Not Dead Yet in Metabolic Regulation” the open access journal Metabolites

Archives

  • February 2023
  • November 2021
  • January 2021
  • October 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • October 2019
  • March 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • January 2017
  • December 2016
  • June 2016
  • May 2016
  • March 2016
  • February 2016
  • May 2015
  • April 2015
  • February 2015
  • January 2015
  • September 2014
  • May 2014
  • September 2013
  • July 2013
  • December 2012
  • January 2011

Archives

  • February 2023
  • November 2021
  • January 2021
  • October 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • October 2019
  • March 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • January 2017
  • December 2016
  • June 2016
  • May 2016
  • March 2016
  • February 2016
  • May 2015
  • April 2015
  • February 2015
  • January 2015
  • September 2014
  • May 2014
  • September 2013
  • July 2013
  • December 2012
  • January 2011

Categories

  • founders in news – en
  • press statement – en

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • CONTACT
  • PRIVACY POLICY
  • IMPRINT
  • DeutschDeutsch
  • LinkedIn
eternygen GmbH 2022
We use cookies – including third-party cookies – to collect information about how visitors use our websites. They help us give you the best possible experience, continually improve our sites and provide you with offers that are tailored to your interests. The information collected via cookies can also be processed outside of the European Union, for example in the USA. By clicking the "Accept all" button you agree to the use of these cookies. Cookie settings Reject ACCEPT ALL
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
SAVE & ACCEPT
Powered by CookieYes Logo